Asset sale Announced

Royalty Pharma acquisition of Neurimmune's royalty interest in AstraZeneca's cliramitug

US$250m consideration

Announced 31 Jul 2026

Advisers

Neurimmune's royalty interest in AstraZeneca's cliramitug

Target

Not disclosed

Royalty Pharma

Acquirer

Target
Neurimmune's royalty interest in AstraZeneca's cliramitug
Acquirer
Royalty Pharma
Seller
Neurimmune
Buyer based in
United States
Seller based in
Switzerland
Sector
Pharma
Tags
Pharma, Biotech

In the league tables

Similar deals

All pharma deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.